Sunitinib and other targeted therapies for renal cell carcinoma

T. Powles*, S. Chowdhury, R. Jones, M. Mantle, P. Nathan, A. Bex, L. Lim, T. Hutson

*Corresponding author for this work

    Research output: Contribution to journalLiterature reviewpeer-review

    45 Citations (Scopus)

    Abstract

    Targeted therapy has radically altered the way metastatic renal cancer is treated. Six drugs are now licensed in this setting, with several other agents under evaluation. Sunitinib is currently the most widely used in the first line setting with impressive efficacy and an established toxicity profile. However, as further randomised studies report and as newer drugs become available this may change. In this review, we address our current understanding of targeted therapy in renal cancer. We also discuss areas in which our knowledge is incomplete, including the identification of correlative biomarkers and mechanisms of drug resistance. Finally, we will describe the major areas of clinical research that will report over the next few years.

    Original languageEnglish
    Pages (from-to)741-745
    Number of pages5
    JournalBJC: British Journal of Cancer
    Volume104
    Issue number5
    DOIs
    Publication statusPublished - 1 Mar 2011

    Keywords

    • renal cancer
    • sunitinib
    • mTOR
    • VEGF
    • PHASE-III TRIAL
    • INTERFERON-ALPHA
    • DOUBLE-BLIND
    • EFFICACY
    • BEVACIZUMAB
    • SORAFENIB
    • INHIBITION
    • GROWTH
    • EVEROLIMUS
    • RESISTANCE

    Fingerprint

    Dive into the research topics of 'Sunitinib and other targeted therapies for renal cell carcinoma'. Together they form a unique fingerprint.

    Cite this